By Chris Wack

 

Inventiva SA ADRs were up 22% to $4.78 after the company said it signed a licensing and collaboration agreement with Chia Tai-Tianqing Pharmaceutical Group Co. to develop and commercialize lanifibranor, Inventiva's proprietary compound for the treatment of non-alcoholic steatohepatitis and potentially other metabolic diseases in mainland China, Hong Kong, Macau and Taiwan.

In exchange for receiving an exclusive license to develop, import, manufacture, commercialize and market lanifibranor in greater China, Chia Tai-Tianqing, a subsidiary of Sino Biopharm, will pay Inventiva an upfront payment of $12 million, and $5 million in the short-term if certain clinical milestones are met.

Under the terms of the agreement, Inventiva has the potential to receive up to $290 million of clinical, regulatory and commercial milestone payments. Inventiva also will receive tiered royalties from high single-digit to mid-teen double digits of net sales made by Sino Biopharm in greater China during the first three years of commercialization and from low to mid-teen double digits starting from year four.

Chia Tai-Tianqing will bear all costs associated with the trials conducted in greater China.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

September 22, 2022 10:23 ET (14:23 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Inventiva
Inventiva (EU:IVA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Inventiva